Could treatment with R-HCVAD/R-MA as compared to R-CHOP truly result in improved outcomes for patients with high-risk diffuse large B cell lymphoma?
Br J Haematol
.
2014 Apr;165(1):145-6.
doi: 10.1111/bjh.12702.
Epub 2013 Dec 19.
Authors
Daniel J Landsburg
1
,
Stephen J Schuster
,
Jakub Svoboda
,
Sunita D Nasta
Affiliation
1
Hematologic Malignancies Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA. daniel.landsburg@uphs.upenn.edu.
PMID:
24354694
DOI:
10.1111/bjh.12702
No abstract available
Keywords:
CHOP; CVAD; MYC; chemotherapy; lymphoma.
Publication types
Letter
Comment
MeSH terms
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Female
Humans
Lymphoma, Large B-Cell, Diffuse / drug therapy*
Male